| 4.42 4.42 (-0.23%) | 04-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.25 | 1-year : | 6.13 |
| Resists | First : | 4.5 | Second : | 5.25 |
| Pivot price | 3.8  |
|||
| Supports | First : | 3.58 | Second : | 3.01 |
| MAs | MA(5) : | 4.31 |
MA(20) : | 3.64 |
| MA(100) : | 3.89 |
MA(250) : | 2.26 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 93.1 |
D(3) : | 90.8 |
| RSI | RSI(14): 67.2  |
|||
| 52-week | High : | 5.78 | Low : | 0.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IRWD ] has closed below upper band by 11.0%. Bollinger Bands are 25.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.46 - 4.48 | 4.48 - 4.5 |
| Low: | 4.3 - 4.33 | 4.33 - 4.35 |
| Close: | 4.38 - 4.42 | 4.42 - 4.45 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Sat, 18 Apr 2026
Ironwood Pharmaceuticals (IRWD) price target increased by 10.31% to 5.46 - MSN
Tue, 14 Apr 2026
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Up - What's Next? - MarketBeat
Fri, 27 Mar 2026
The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment - Stock Titan
Wed, 25 Feb 2026
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Q4 Miss but Provides Robust 2026 Outlook - ChartMill
Wed, 25 Feb 2026
IRONWOOD PHARMACEUTICALS ($IRWD) Releases Q4 2025 Earnings - Quiver Quantitative
Wed, 04 Feb 2026
Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 163 (M) |
| Shares Float | 126 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 92 (%) |
| Shares Short | 17,900 (K) |
| Shares Short P.Month | 12,920 (K) |
| EPS | 0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.62 |
| Profit Margin | 8.1 % |
| Operating Margin | 13.7 % |
| Return on Assets (ttm) | 19.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -47.3 % |
| Gross Profit (p.s.) | 1.23 |
| Sales Per Share | 1.81 |
| EBITDA (p.s.) | 0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 127 (M) |
| Levered Free Cash Flow | 112 (M) |
| PE Ratio | 29.46 |
| PEG Ratio | 0 |
| Price to Book value | -2.75 |
| Price to Sales | 2.43 |
| Price to Cash Flow | 5.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|